PRP & Exosome Hair Therapy

Texas Hair Restoration Dallas (McGrath Medical) offers non-surgical hair loss therapies including PRP (platelet-rich plasma) combined with ACell MatriStem, and the clinic's current primary option — Pure Bone Marrow Exosome (PBME) therapy delivered with microneedling. Exosome and Extracellular Vesicle (EV) therapies introduce regenerative signalling molecules to dormant or weakened follicles to reactivate growth cycles. Low-level laser therapy (Capillus) and FDA-approved pharmaceutical management with Finasteride and Minoxidil round out the non-surgical menu. These treatments can be used as standalone therapies or as adjuncts to surgical restoration.

Texas Hair Restoration Dallas provides a structured non-surgical hair loss treatment programme built around regenerative biologics and medical therapies. The practice pioneered ACell + PRP combination therapy in Texas — a protocol that pairs platelet-rich plasma with ACell MatriStem (an extracellular matrix product derived from porcine urinary bladder) to create a dual growth-factor and scaffold stimulus in the perifollicular tissue. The ACell matrix provides structural support and a sustained release environment for the growth factors carried in the PRP, prolonging the regenerative signal at the target site. The clinic has since transitioned its primary non-surgical offering to Pure Bone Marrow Exosome (PBME) therapy, a more advanced regenerative approach. Exosomes are nanoscale extracellular vesicles secreted by mesenchymal stem cells; they carry a payload of growth factors, cytokines, microRNA, and signalling proteins that modulate the Wnt/β-catenin and other pathways central to hair follicle cycling. When injected into the scalp in areas of thinning, PBME therapy aims to shift follicles from the telogen (resting) phase back into the anagen (active growth) phase, and to extend anagen duration in follicles that have been miniaturising under androgenetic influence. PBME is delivered via intradermal injection combined with microneedling to maximise dermal penetration and distribution across the treatment zone. An Extracellular Vesicle (EV) therapy variant is also available for patients seeking the most advanced regenerative formulations. Platelet-Rich Plasma therapy prepared from the patient's own blood remains available as an established, well-documented option: centrifugation concentrates platelets three to five times above baseline whole-blood levels, and the resulting plasma — rich in PDGF, TGF-β, VEGF, and EGF — is injected directly into the scalp to stimulate perifollicular vascularity and fibroblast activity. An initial course of three to four monthly injections is standard, followed by maintenance sessions at four to six month intervals. Low-level laser therapy (LLLT) using the Capillus wearable device applies photobiomodulation to the scalp — specific red wavelengths (630–670 nm) are absorbed by cytochrome c oxidase in follicular mitochondria, increasing ATP production and reducing oxidative stress in the perifollicular microenvironment. The iGrow home laser system provides an additional at-home device option. Oral and topical FDA-approved medications including Finasteride (5α-reductase inhibitor, reducing DHT-mediated follicle miniaturisation) and Minoxidil (vasodilator with direct follicle-stimulatory effects) are prescribed as part of combination protocols. A multi-modality combination approach can integrate any of the above therapies for patients who are not yet surgical candidates or who wish to optimise the results of a prior transplant.